Dong OM. Using the diffusion of innovation theory to understand the challenges and opportunities to advancing use of nutrigenetics in clinical practice. Lifestyle Genom. 2021 Dec;14(4):124-8. doi: 10.1159/000517760
Zeisel SH, Niculescu MD, Meyer KA, Dong OM, Chmurzynska A, Kohlmeier M. Precision nutrition. A nutrigenetic-based framework to establish guidelines for choline intake. Presented at the 2019 Congress of the International Society of Nutrigenetics & Nutrigenomics; July 13, 2019. Cambridge, United Kingdom. [abstract] Lifestyle Genom. 2018; 11:178. doi: 10.1159/000501177
Dong OM. Pharmaconutrigenetics of antipsychotic-induced weight gain. Presented at the Congress of the International Society of Nutrigenetics & Nutrigenomics; July 12, 2019. Cambridge, UK. [abstract] Lifestyle Genom. 2018; 11.
Yosipovitch G, Reaney M, Eckert L, Nelson L, Clark M, Abbe A, Ardeleanu M, Radin A, Gadkari A. Validation of the peak pruritus numerical rating scale: results from clinical studies of dupilumab in adults with moderate-to-severe atopic dermatitis. Poster presented at the Australasian College of Dermatologists 50th Annual Scientific Meeting; May 2017. Sydney, Australia. [abstract] Australas J Dermatol. 2017 May; 58(S1):106-7. Previously presented at the 2017 American Academy of Dermatology Annual Meeting. doi: 10.1111/ajd.21_12652
Cusack K, Jonas DE, Forneris CA, Wines C, Sonis J, Middleton JC, Feltner C, Brownley KA, Olmsted KR, Greenblatt A, Weil A, Gaynes BN. Psychological treatments for adults with posttraumatic stress disorder: a systematic review and meta-analysis. Clin Psychol Rev. 2016 Feb;43:128-41. doi: 10.1016/j.cpr.2015.10.003
Spelman LJ, Lebwohl M, Mordin M, Mallya UG, Gnanasakthy A, Fox T. Secukinumab treatment provides fast relief from patient-reported psoriasis burden. Poster presented at the 48th Australasian College of Dermatologists Annual Scientific Meeting; May 2015. Adelaide, Australia. [abstract] Australas J Dermatol. 2015 May; 56(Suppl 2):73.
Foley P, Sherif B, Mallya UG, Fox T, Gottlieb AB. Secukinumab treatment sustains patient-reported outcome benefits through 1 year. Poster presented at the 48th Australasian College of Dermatologists Annual Scientific Meeting; May 2015. Adelaide, Australia. [abstract] Australas J Dermatol. 2015 May; 56(Suppl 2):56.
Sinclair R, McLeod L, Mallya UG, Fox T, Strober B. Psoriasis patients with PASI90 response achieve greater health-related quality of life improvements than those with PASI75 response. Poster presented at the 48th Australasian College of Dermatologists Annual Scientific Meeting; May 2015. Adelaide, Australia. [abstract] Australas J Dermatol. 2015 May; 56(S2):68.